Professor Jacob Sherkow has co-authored a new paper with Glenn Cohen (Harvard) and Eli Y. Adashi (Brown) titled "Assessing—and Extending—California’s Insulin Manufacturing Initiative." The paper, which was published in JAMA, reviews a novel attempt by the state of California to lower prescription drug costs by turning the state into the supplier, and the challenges it might face as well as broader implications. 

Sherkow also spoke to the Illinois News Bureau about the paper. 

“The policy implications are enormous,” he said. “If CalRx were to succeed, it could serve as a model for drug manufacturing beyond just insulin. It could address gaps in drug shortages, which is an under-the-radar problem in drug policy, especially where the drugs serve small patient populations or drugs that are cost-prohibitive for patients.”

Read the paper at jamanetwork.com.